Drug Approvals, Upbeat Earnings Help Vertex Pharmaceuticals’ Stock Jump 20% In A Month

by Trefis Team
Rate   |   votes   |   Share

Vertex Pharmaceuticals (NASDAQ: VRTX)  is an American biopharmaceutical company mainly focused on developing and commercializing therapies for the treatment of cystic fibrosis. Vertex has seen its stock price rise 15% over the last month, driven in part by the U.S. Food and Drug Administration (FDA) approval for its drug Trikafta, which is used for treating cystic fibrosis in individuals aged 12 and older, and also thanks to reasonably strong Q3’19 results that were released in late October. Another factor that helped the company’s stock was the recent agreement it reached with the government of England, Wales and Northern Ireland for patients across U.K. to access its drugs Orkambi, Symkevi and Kalydeco.

View our interactive dashboard analysis on Why Has Vertex Pharmaceuticals’ Stock Gained 20% Over The Last Month?

How does Vertex Pharmaceuticals’ Revenue Growth 2018 compare with that in prior periods and what’s the forecast?

Total Revenues for Vertex Pharmaceuticals significantly increased from $2.49 Bil in 2017 to $3.05 Bil in 2018; an increase of 22.5%.

This compares with Total Revenues growth of:

  • 9% in 2015 compared to 2014
  • 9% in 2016 compared to 2015
  • 2% in 2017 compared to 2016

We expect Total Revenues to grow 23% in 2019.

 

How does Vertex Pharmaceuticals’ Total Expense in 2018 compare with that in prior periods and what’s the forecast?

Total Expense for Vertex Pharmaceuticals decreased slightly from $2.50 Bil in 2017 to $2.45 Bil in 2018; a decrease of -2.28%.

This compares with Total Expense growth of:

  • 9% in 2015 compared to 2014
  • 3% in 2016 compared to 2015
  • 5% in 2017 compared to 2016

We expect Total Expense growth to be 18.4% in 2019.

 

How does Vertex Pharmaceuticals’ EBT 2018 compare with that in prior periods and what’s the forecast?

EBT for Vertex Pharmaceuticals swung from -$15.7 Mil in 2017 to $600 Mil in 2018. We expect EBT to increase 41.9% to $852 Mil in 2019.

 

How does Vertex Pharmaceuticals’ Net Income 2018 and EPS compare with that in prior periods and what’s the forecast?

For more information on the Vertex  Pharmaceuticals’ Net Income and EPS, view our interactive dashboard analysis.

 

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs
For CFOs and Finance Teams | Product, R&D, and Marketing Teams
More Trefis Data
Like our charts? Explore example interactive dashboards and create your own

Rate   |   votes   |   Share

Comments

Name (Required)
Email (Required, but never displayed)
Be the first to comment!